Clinical Trial News and Research

RSS

Thomson Reuters adds Cortellis Clinical Trials Intelligence for drug discovery and development

The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced the addition of Clinical Trials Intelligence to the Thomson Reuters CortellisTM suite, the industry's most comprehensive information solution for drug discovery and development.

19 Oct 2013

Opsumit drug receives FDA approval to treat adults with pulmonary arterial hypertension

The U.S. Food and Drug Administration today approved Opsumit (macitentan), a new drug to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or the need for lung transplantation.

19 Oct 2013

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

ARIAD Pharmaceuticals, Inc. today announced that it is discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial of Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukemia.

18 Oct 2013

pSivida reports that Alimera Sciences gets FDA Complete Response Letter for ILUVIEN NDA

pSivida Corp., a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that its licensee Alimera Sciences, Inc. has received a Complete Response Letter for the New Drug Application for ILUVIEN from the U.S. Food and Drug Administration.

18 Oct 2013

GenSpera to present G-202 Phase I trial in hepatocellular carcinoma at EORTC-NCI-AACR Symposium

GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, will present data from the G-202 Phase I clinical trial at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA on Monday, October 21st.

18 Oct 2013

Two drugs in combination improve survival in patients with advanced pancreatic cancer

Investigators at the Vall d´Hebron University Hospital and the Vall d'Hebron Institute of Oncology (VHIO), have participated in an international phase III study, published in The New England Journal of Medicine.

18 Oct 2013

NEJM publishes Celgene’s Abraxane phase III study results

Published today in the New England Journal of Medicine, a phase III clinical trial of Abraxane (paclitaxel formulated as albumin-bound nanoparticles) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone [(median of 8.5 vs. 6.7 months) (HR 0.72, P=0.000015)].

17 Oct 2013

King's College researchers identify new biomarker that detects sepsis in blood

Researchers at King's College London have identified a biomarker - a biological 'fingerprint' - for sepsis in the blood, and showed it could be possible to diagnose the condition within two hours by screening for this biomarker at a patient's bedside.

17 Oct 2013

BRAF inhibitor vemurafenib effective for patients with papillary thyroid cancer

Mutations in a gene that codes for the enzyme BRAF kinase have been associated with increased risk for papillary thyroid cancer. An early-stage clinical trial of the BRAF inhibitor vemurafenib resulted in either a partial response or stable disease in patients with PTC and BRAF mutations.

17 Oct 2013

Researchers discover why women with BRCA gene develop breast and ovarian cancer

Researchers announced today in the journal Lancet Oncology that they are well on the way to discovering why women with the faulty genes BRCA 1 and BRCA 2, one of which was inherited by the actress Angelina Jolie, develop breast and ovarian cancer rather than other cancers.

17 Oct 2013

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE® in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine.

17 Oct 2013

Researchers develop simple blood test to identify patient with Irritable Bowel Syndrome

For the first time, a simple blood test may be the best way to determine if a patient is suffering from Irritable Bowel Syndrome, or another serious condition such as Inflammatory Bowel Disease, according to Cedars-Sinai physician researcher Mark Pimentel, MD, lead author of a multicenter clinical trial.

17 Oct 2013

Certain blood pressure medications may reduce risk of dementia due to Alzheimer's disease

A Johns Hopkins-led analysis of data previously gathered on more than 3,000 elderly Americans strongly suggests that taking certain blood pressure medications to control blood pressure may reduce the risk of dementia due to Alzheimer's disease.

17 Oct 2013

Imaxio Sells Genomics Division To Hybrigenics

...

16 Oct 2013

CEL-SCI, Ergomed To Co-Develop Head And Neck Cancer Candidate As Potential HPV Treatment

...

16 Oct 2013

Respicardia awarded U.S. Healthcare Product of the Year for remede System

Respicardia®, Inc., a developer of implantable therapies to improve respiratory and cardiovascular health, announced that it has been awarded the U.S. Healthcare Product of the Year by Acquisition International for the remede System, the first and only implantable device for the treatment of central sleep apnea.

16 Oct 2013

Clinical Trial News and Research

Thomson Reuters adds Cortellis Clinical Trials Intelligence for drug discovery and development

Opsumit drug receives FDA approval to treat adults with pulmonary arterial hypertension

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

pSivida reports that Alimera Sciences gets FDA Complete Response Letter for ILUVIEN NDA

GenSpera to present G-202 Phase I trial in hepatocellular carcinoma at EORTC-NCI-AACR Symposium

Two drugs in combination improve survival in patients with advanced pancreatic cancer

NEJM publishes Celgene’s Abraxane phase III study results

King's College researchers identify new biomarker that detects sepsis in blood

BRAF inhibitor vemurafenib effective for patients with papillary thyroid cancer

Researchers discover why women with BRCA gene develop breast and ovarian cancer

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Researchers develop simple blood test to identify patient with Irritable Bowel Syndrome

Certain blood pressure medications may reduce risk of dementia due to Alzheimer's disease

Imaxio Sells Genomics Division To Hybrigenics

CEL-SCI, Ergomed To Co-Develop Head And Neck Cancer Candidate As Potential HPV Treatment

Respicardia awarded U.S. Healthcare Product of the Year for remede System

Researchers test ATR-101 compound in clinical trial for adrenal cancer

Results of Phase 3 clinical trial of contraceptive vaginal ring presented by Population Council

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Ghrelin hormone released during chronic stress may predispose people to PTSD

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery